Surf Bio announced today that it raised $16 million in seed funding to advance its drug delivery offerings for treating diabetes. Palo Alto, California-based Surf Bio plans to use the funds to advance its polymer-based drug delivery platform and accelerate the development of ultra-rapid insulin for treating diabetes. Get the full story at our sister […]
Diabetes
Welcome to MassDevice's Diabetes Hub, your resource for the latest news in diabetes technology. Stay informed about the innovations and business news shaping the diabetes device industry.
Here are top diabetes features from MassDevice and its sister publications (and scroll down to read the latest diabetes device news from MassDevice):
+ These diabetes devices are set to launch in 2024
+ The top IVD and diabetes tech stories of 2023
+ How Dexcom designed a new “life-changing” sensor for even more people with diabetes
+ Embecta CEO sees GLP-1 opportunities as company progresses on insulin patch pump
+ The 10 biggest diabetes tech stories from 2023
Latest Diabetes News
Study supports use of Prevencio’s blood test in risk classification of patients with diabetes
Prevencio announced today that patient data demonstrate high accuracy with its artificial intelligence (AI)-driven HART CVE blood test. Kirkland, Washington-based Prevencio presented data at last week’s American College of Cardiology (ACC) Scientific Sessions that suggested that the HART CVE blood test significantly improves the risk classification for patients with diabetes, allowing for more aggressive therapy in […]
Diabeloop announces integration of insulin automatization software for use with insulin pens
Diabeloop announced today that it leveraged its diabetes management software to integrate insulin pens into its hybrid closed-loop system. Paris-based Diabeloop’s DBL-4pen, a unique app, offers new opportunities for the personalized management of people with type 1 and type 2 diabetes. Get the full story at our sister site, Drug Delivery Business News.
DiabetesWise launches platform for provider decision-making on diabetes devices
DiabetesWise announced that it launched its DiabetesWise Pro website to help providers make informed decisions on diabetes devices. Stanford, California–based DiabetesWise says it designed the website as an easy-to-use and free tool for providers to access in the clinical practice or at the point of care. They can identify the best available diabetes device on […]
Senseonics announces first Eversense E3 CGM implant in U.S.
Senseonics (NYSE:SENS) announced today that the first patient was implanted with its next-generation Eversense E3 continuous glucose monitor. Germantown, Maryland-based Senseonics, in partnership with Ascensia Diabetes Care, launched the Eversense E3 long-term implantable CGM system in the U.S. earlier this week. The system received FDA approval in February for use lasting up to six months (180 days), making […]
Analysts see Medtronic’s diabetes, spine businesses as most likely spinoff candidates
Needham analysts published a report singling out the diabetes and spine businesses as possible spinoff options for Medtronic (NYSE:MDT). Mike Matson, David Saxon and Joseph Conway of Needham pointed to previous comments from Medtronic management that indicate the potential for changes in the coming year, with a spinoff of a large business within Medtronic considered […]
Better Therapeutics reaches key milestones for prescription digital therapeutics
Better Therapeutics (Nasdaq:BTTX) announced today that it hit multiple key research milestones as it validates its digital therapeutics. San Francisco-based Better Therapeutics develops prescription digital therapeutics designed to deliver a novel form of cognitive-behavioral therapy for treating cardiometabolic diseases, potentially improving key measures related to type 2 diabetes, hypertension and more. Get the full story at […]
How Embecta is ‘uniquely positioned’ in diabetes space following spinoff from BD
Unlike most “new” companies, Embecta enters the playing field with nearly a century of history in diabetes. Nearly one year after BD (NYSE:BDX) announced its intent to spinoff its diabetes business, Embecta (Nasdaq:EMBC) now stands on its own. On April 1, the spinoff was made official, and Embecta became a standalone, publicly-traded company aiming to make waves in the diabetes […]
FDA approves IDE trial for Fractyl Health’s diabetes reversal tech in type 2 diabetes patients
Fractyl Health announced today that it received FDA approval for an investigational device exemption (IDE) trial of its diabetes reversal platform. Lexington, Massachusetts-based Fractyl Health will evaluate its Revita treatment in patients with type 2 diabetes whose disease is inadequately controlled despite treatment with at least two antidiabetic agents (ADAs) and who are not yet on […]
Ascensia launches Senseonics’ next-gen 180-day Eversense E3 CGM in U.S.
Ascensia Diabetes Care announced today that it launched the Senseonics (NYSE:SENS) Eversense E3 system in the U.S. The next-generation Eversense E3 continuous glucose monitoring (CGM) system, developed by Germantown, Maryland-based Senseonics, received FDA approval in February for use lasting up to six months (180 days), making it the longest-lasting CGM sensor available in the U.S. Get the full story […]
Dexcom launches Dexcom One CGM in the UK
Dexcom (NSDQ:DXCM) announced today that it launched the new Dexcom One continuous glucose monitoring (CGM) system in the United Kingdom. San Diego–based Dexcom designed the Dexcom One system as an easy-to-use, real-time CGM (rt-CGM) that it aims to make more affordable and accessible for people with diabetes in the UK. Get the full story at our […]